<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578370</url>
  </required_header>
  <id_info>
    <org_study_id>ISD001-CI-07</org_study_id>
    <secondary_id>2007-002947-26</secondary_id>
    <nct_id>NCT00578370</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test</brief_title>
  <official_title>A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Ciclosporin in a Psoriasis Plaque Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISDIN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISDIN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ciclosporin is a cyclic nonribosomal polypeptide of 11 amino acids produced by the fungi&#xD;
      Tolypocladium inflatum and Cylindrocarpon lucidum. Ciclosporin is a highly efficient&#xD;
      immunosuppressant drug widely used in post-allergenic organ transplant to reduce the activity&#xD;
      of the subject's immune system and so the risk of organ rejection. Apart from transplant&#xD;
      medicine, ciclosporin is also used in the treatment of autoimmune diseases like psoriasis and&#xD;
      infrequently in rheumatoid arthritis and related diseases, although it is only used in severe&#xD;
      cases.&#xD;
&#xD;
      Ciclosporin blocks the lymphocytes, especially the T-lymphocytes, in the G0- or G1-phase of&#xD;
      the cell cycle. Moreover it inhibits the production and release of lymphokines including&#xD;
      interleukin 2 or the T-cell growth factor.&#xD;
&#xD;
      Generally ciclosporin is taken orally (capsule or solution)or by injection in doses of 1.5 to&#xD;
      5.5 mg/kg/day. In the topical cutaneous emulsion presented here, ciclosporin is available at&#xD;
      a concentration of 0.5 and 1.5%.&#xD;
&#xD;
      The purpose of this study is the demonstration of antipsoriatic efficacy and tolerability of&#xD;
      topical cutaneous ciclosporin in subjects with psoriasis vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a common dermatological disorder, consisting of both an inflammatory and a&#xD;
      hyperproliferative component. Scaly, erythematous infiltrated skin lesions are indicative of&#xD;
      psoriasis vulgaris. The disease is characterized micromorphologically by epidermal&#xD;
      hyperplasia with incomplete differentiation, intraepidermal accumulation of polymorphonuclear&#xD;
      neutrophils, elongated papillae containing dilated, tortuous capillaries and&#xD;
      lymphohistiocytic infiltrate.&#xD;
&#xD;
      Since the underlying cause of the disease remains unknown, causal therapy is not possible.&#xD;
      The complex clinical picture necessitates a polypragmatic therapeutic approach. Typical&#xD;
      therapies include phototherapy and photochemotherapy, topical treatment with corticosteroids,&#xD;
      vitamin D3 analogs, coal-tar preparations and dithranol, and systemic treatment with&#xD;
      retinoids, methotrexate and ciclosporin (oral or injection).&#xD;
&#xD;
      In the present study the topical cutaneous ciclosporin formulation for topical treatment of&#xD;
      psoriasis will be tested in low-dose for efficacy and tolerability. Two concentrations of the&#xD;
      ciclosporin formulation (0.5% and 1.5%), the corresponding vehicle, a marketed corticoid&#xD;
      preparation and a marketed topical Vitamin-D-analog will be tested simultaneously in the same&#xD;
      patient. Five test fields located at the torso and at the extremities will be examined per&#xD;
      subject, and will be treated non-occlusively on 22 study days over a period study of 26 days.&#xD;
&#xD;
      Experimental measurements (sonography) and clinical assessments will be performed at baseline&#xD;
      and on some study days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriatic infiltrate measured by sonography</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin condition measured by scoring</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin 0.5% (Formulation 01B)</intervention_name>
    <description>Cutaneous emulsion 200µl once a day (26 days)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin 1.5% (Formulation 02B)</intervention_name>
    <description>Cutaneous emulsion 200µl once a day (26 days)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% betamethasone</intervention_name>
    <description>Solution 200µl once a day (26 days)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Betnesol V crinale 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.005% calcipotriol</intervention_name>
    <description>Solution 200µl once a day (26 days)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Daivonex solution 0.005%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation 00B</intervention_name>
    <description>Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic plaque type psoriasis&#xD;
&#xD;
          -  Sexually active females of childbearing potential should either be surgically sterile&#xD;
             (hysterectomy or tubal ligation), or should use a highly effective medically accepted&#xD;
             contraceptive regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4&#xD;
             weeks preceding and during the study (corticosteroids 8 weeks)&#xD;
&#xD;
          -  Systemic treatment with antipsoriatics or therapy with PUVA, selected ultraviolet&#xD;
             photo therapy in the three months preceding and during the study&#xD;
&#xD;
          -  Treatment with systemic or locally acting medications which might counter or influence&#xD;
             the study aim&#xD;
&#xD;
          -  Previous therapy with methotrexate over many years&#xD;
&#xD;
          -  Therapy with nephrotoxic medication&#xD;
&#xD;
          -  Therapy with digoxin, colchicin and statins&#xD;
&#xD;
          -  Medications which might influence the potassium metabolism&#xD;
&#xD;
          -  Subjects with known dysfunction of the calcium metabolism&#xD;
&#xD;
          -  Subjects with increased uric acid or potassium serum levels&#xD;
&#xD;
          -  Erythrodermic psoriasis, psoriasis punctata and pustular psoriasis or extended chronic&#xD;
             stationary forms of psoriasis&#xD;
&#xD;
          -  Subjects with acute virus infection&#xD;
&#xD;
          -  Subjects with acne, anogenital pruritus, rosacea, perioral dermatitis, specific skin&#xD;
             problems (skin tuberculosis, luetic skin diseases), vaccination reactions, skin&#xD;
             infections caused by bacteria or viruses&#xD;
&#xD;
          -  Symptoms of a clinically significant illness that may influence the outcome of the&#xD;
             study in the four weeks before and during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Gassmueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioskin GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioskin</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol. 1972;52(1):43-8.</citation>
    <PMID>4111105</PMID>
  </reference>
  <reference>
    <citation>Wendt H, Frosch PJ. Psoriasis-Plaque Test. 31 - 35 in: Clinico-pharmacological models for the assay of topical corticoids. Wendt H, Frosch PJ (eds.) 1982, Karger Verlag, Basel</citation>
  </reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <last_update_submitted>November 4, 2008</last_update_submitted>
  <last_update_submitted_qc>November 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>ISDIN</name_title>
    <organization>ISDIN</organization>
  </responsible_party>
  <keyword>Ciclosporin</keyword>
  <keyword>Plaque type psoriasis</keyword>
  <keyword>Psoriasis plaque test</keyword>
  <keyword>Sonography</keyword>
  <keyword>Cyclosporin</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

